1 |
Stewart B (2014). World cancer report 2014. World Health Organization.
|
2 |
Brock MV, Hooker CM, Ota-Machida E, et al (2008). DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med, 358, 1118-28.
DOI
|
3 |
DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
DOI
|
4 |
Dickersin K, Berlin JA (1992). Meta-analysis: state-of-thescience. Epidemiol Rev, 14, 154-76.
|
5 |
Dong SM, Lee EJ, Jeon ES, et al (2005). Progressive methylation during the serrated neoplasia pathway of the colorectum. Mod Pathol, 18, 170-8.
DOI
|
6 |
Esteller M, Sanchez-Cespedes M, Rosell R, et al (1999). Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res, 59, 67-70.
|
7 |
Feng Q, Hawes SE, Stern JE, et al (2007). Promoter hypermethylation of tumor suppressor genes in urine from patients with cervical neoplasia. Cancer Epidemiol Biomarkers Prev, 16, 1178-84.
DOI
|
8 |
Feng Q, Hawes SE, Stern JE, et al (2008). DNA methylation in tumor and matched normal tissues from non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev, 17, 645-54.
DOI
|
9 |
Hanabata T, Tsukuda K, Toyooka S, et al (2004). DNA methylation of multiple genes and clinicopathological relationship of non-small cell lung cancers. Oncol Rep, 12, 177-80.
|
10 |
Hsu HS, Chen TP, Hung CH, et al (2007). Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma. Cancer, 110, 2019-26.
DOI
|
11 |
Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
DOI
|
12 |
Jin M, Kawakami K, Fukui Y, et al (2009). Different histological types of non-small cell lung cancer have distinct folate and DNA methylation levels. Cancer Sci, 100, 2325-30.
DOI
|
13 |
Kim DS, Kim MJ, Lee JY, et al (2007). Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features. Cancer, 110, 2785-92.
DOI
ScienceOn
|
14 |
Kim H, Kwon YM, Kim JS, et al (2006). Elevated mRNA levels of DNA methyltransferase-1 as an independent prognostic factor in primary nonsmall cell lung cancer. Cancer, 107, 1042-9.
DOI
|
15 |
Kim H, Kwon YM, Kim JS, et al (2004). Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer. J Clin Oncol, 22, 2363-70.
DOI
|
16 |
Kontic M, Stojsic J, Jovanovic D, et al (2012). Aberrant promoter methylation of CDH13 and MGMT genes is associated with clinicopathologic characteristics of primary non-small-cell lung carcinoma. Clin Lung Cancer, 13, 297-303.
DOI
ScienceOn
|
17 |
Lee SW (1996). H-cadherin, a novel cadherin with growth inhibitory functions and diminished expression in human breast cancer. Nat Med, 2, 776-82.
DOI
|
18 |
Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
|
19 |
Li L, Choi JY, Lee KM, et al (2012). DNA methylation in peripheral blood: a potential biomarker for cancer molecular epidemiology. J Epidemiol, 22, 384-94.
DOI
|
20 |
M. Egger GDS, M. Schneider, and C. Minder (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ Open.
|
21 |
Mikeska T, Bock C, Do H, et al (2012). DNA methylation biomarkers in cancer: progress towards clinical implementation. Expert Rev Mol Diagn, 12, 473-87.
DOI
|
22 |
Riou P, Saffroy R, Chenailler C, et al (2006). Expression of T-cadherin in tumor cells influences invasive potential of human hepatocellular carcinoma. Faseb J, 20, 2291-301.
DOI
|
23 |
Sato M, Mori Y, Sakurada A, et al (1998). The H-cadherin (CDH13 ) gene is inactivated in human lung cancer. Human Genetics, 103, 96-101.
DOI
|
24 |
Suzuki M, Shigematsu H, Iizasa T, et al (2006). Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer. Cancer, 106, 2200-7.
DOI
|
25 |
Takeuchi T, Ohtsuki Y (2001). Recent progress in T-cadherin (CDH13 , H-cadherin) research. Histol Histopathol, 16, 1287-93.
|
26 |
Toyooka KO, Toyooka S, Virmani AK, et al (2001). Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res, 61, 4556-60.
|
27 |
Toyooka S, Maruyama R, Toyooka KO, et al (2003). Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer, 103, 153-60.
DOI
|
28 |
Yanagawa N, Tamura G, Oizumi H, et al (2007). Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers. Lung Cancer, 58, 131-8.
DOI
|
29 |
Tsou JA, Galler JS, Siegmund KD, et al (2007). Identification of a panel of sensitive and specific DNA methylation markers for lung adenocarcinoma. Mol Cancer, 6, 70.
|
30 |
Ulivi P, Zoli W, Calistri D, et al (2006). p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients. J Cell Physiol, 206, 611-5.
DOI
|
31 |
Zhai X, Li SJ (2014). Methylation of RASSF1A and CDH13 genes in individualized chemotherapy for patients with nonsmall cell lung cancer. Asian Pac J Cancer Prev, 15, 4925-8.
DOI
|
32 |
Zhang Y, Wang R, Song H, et al (2011). Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Cancer Lett, 303, 21-8.
DOI
|
33 |
Zhong Y, Delgado Y, Gomez J, et al (2001). Loss of H-cadherin protein expression in human non-small cell lung cancer is associated with tumorigenicity. Clin Cancer Res, 7, 1683-7.
|